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Identification of the Human Herpesvirus 6A gQ1 Domain Essential
for Its Functional Conformation
Takahiro Maeki,a,b Mayuko Hayashi,a,b Akiko Kawabata,a,b Huamin Tang,a,b Koichi Yamanishi,c Yasuko Moria,b
Division of Clinical Virology, Kobe University Graduate School of Medicine, Kobe, Japana; Laboratory of Virology and Vaccinology, Division of Biomedical Research,
National Institute of Biomedical Innovation, Ibaraki, Osaka, Japanb; National Institute of Biomedical Innovation, Ibaraki, Osaka, Japanc
Human herpesvirus 6 is a T lymphotropic herpesvirus, long classified into variants A and B (HHV-6A and HHV-6B) based on
differences in sequence and pathogenicity. Recently, however, HHV-6A and HHV-6B were reclassified as different species. Here,
we isolated a neutralizing monoclonal antibody (Mab) named AgQ 1-1 that was specific for HHV-6A glycoprotein Q1 (AgQ1),
and we showed that amino acid residues 494 to 497 of AgQ1 were critical for its recognition by this Mab. This region was also
essential for AgQ1’s complex formation with gH, gL, and gQ2, which might be important for viral binding to the cellular recep-
tor, CD46. In addition, amino acid residues 494 to 497 are essential for viral replication. Interestingly, this sequence corresponds
to the domain on HHV-6B gQ1 that is critical for recognition by an HHV-6B-specific neutralizingMab.Within this domain,
only Q at position 496 of HHV-6A is distinct from the HHV-6B sequence; however, the mutant AgQ1(Q496E) was still clearly
recognized by theMab AgQ 1-1. Surprisingly, replacement of the adjacent amino acid, in mutant AgQ1(C495A), resulted in poor
recognition byMab AgQ 1-1, and AgQ1(C495A) could not form the gH/gL/gQ1/gQ2 complex. Furthermore, the binding ability
of mutant AgQ1(L494A) with CD46 decreased, although it could form the gH/gL/gQ1/gQ2 complex and it showed clear reactiv-
ity to Mab AgQ 1-1. These data indicated that amino acid residues 494 to 497 of AgQ1 were critical for the recognition byMab
AgQ 1-1 and essential for AgQ1’s functional conformation.
Human herpesvirus 6 (HHV-6) was first isolated in 1986 frompatients with lymphoproliferative disorders (1). HHV-6 was
originally classified into two variants, HHV-6A and -B, based on
differences in their genetic characteristics and cell tropism (2–5).
However, quite recently, HHV-6A and HHV-6B were reclassified
into different species (according to the Virus Taxonomy List
2011). HHV-6B is the causative agent of exanthem subitum (6)
andmainly causes reactivation in immunocompromised hosts (7,
8), while HHV-6A is involved in the etiology of several diseases,
including multiple sclerosis (9), encephalitis (10), and Hashimo-
to’s thyroiditis (11). Almost all children have antibodies against
HHV-6A or HHV-6B by 2 years of age (12). Although HHV-6B
has been reported to be responsible for primary infections in
many countries (13–15), primaryHHV-6A infectionhas been also
reported in Africa (16). Both variants can infect the brain, but
HHV-6A is thought to be more neurotropic than HHV-6B (17).
Several reports have shown that the reactivation of HHV-6A and
-B may contribute to several diseases in immunosuppressed pa-
tients (18–20).
HumanCD46, a regulator of the complement activation recep-
tor expressed on all nucleated cells, is a cellular receptor for
HHV-6 (21), andHHV-6A’s viral ligand is the envelope glycopro-
tein complex (gH/gL/gQ1/gQ2) (22, 23). Furthermore, we previ-
ously found that the HHV-6A gH/gL/gQ1/gQ2 complex forma-
tion itself is important for HHV-6A’s trafficking and CD46
binding, thus indicating that the correct folding could not be done
without either of those (24). Moreover, in experiments using re-
combinant viruses, we proved that HHV-6A gQ1 and gQ2 genes
are essential genes for virus growth (24, 25).
The gQ1 and gQ2 proteins are conserved in roseoloviruses, but
the amino acid identities between HHV-6A strain U1102 and
HHV-6B strain HST are 78.0% and 68.7%, respectively. Since the
average amino acid identity between HHV-6A U1102 and
HHV-6BHSTwas about 94% (26), gQ1 and gQ2 appear to be key
genes for determining various biological differences between
HHV-6A and -B. Although the function of HHV-6B gQ1 was
unknown, we previously obtained an HHV-6B-specific neutraliz-
ing antibody that recognizes a conformational epitope for gQ1,
indicating thatHHV-6B gQ1, like the gQ1 ofHHV-6A, plays a key
role in virus infection, especially in cell entry (27). Therefore, to
elucidate the viral entry mechanism, it was important to analyze
the structure and function of gQ1 in more detail.
In this study, we produced a neutralizing antibody that specif-
ically recognizes the gQ1ofHHV-6A andnot that ofHHV-6B.We
found that the critical domain of gQ1 for antibody recognition
was conserved between HHV-6A and -B, although the specific
neutralizing antibodies for each virus had distinct determinant(s)
in HHV-6A and -B. We further found that the identified domain
was also essential for the formation of theHHV-6A gQ1, gQ2, gH,
and gL complex, its CD46 binding, and viral replication.
MATERIALS AND METHODS
Cells and viruses. Human embryonic kidney (HEK) 293T cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 8% fetal bovine serum (FBS), 20!g/ml gentamicin, and L-glutamine
(0.584 g/liter). Umbilical cord blood mononuclear cells (CBMCs) were
prepared as described previously (28, 29). CBMCs were kindly provided
byKazushigeAdachi (MinohCityHospital) andHidetoYamada (Depart-
ment of Obstetrics and Gynecology, Kobe University Graduate School of
Medicine) and purchased from Cell Bank of RIKEN Bioresource Center
(RIKEN; the Institute of Physical and Chemical Research, Japan). This
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study was approved by the ethical committees of all the institutions in-
volved.
Plasmid construction. Plasmids expressing HHV-6A gH, gL, gQ1,
and gQ2 were described previously (24). To construct plasmids express-
ing the HHV-6A gQ1 carboxyl-terminal deletion mutants AgQ1("1266),
AgQ1("1440), AgQ1("1476), AgQ1("1512), and AgQ1("1533), each
gQ1 fragment was amplified by the appropriate primer pair, digested
with EcoRI and XhoI, and ligated into a digested pcDNA 3.1(#) vector.
The HHV-6A gQ1 point mutants AgQ1(L494A), AgQ1(C495A),
AgQ1(Q496A), AgQ1(Q496E), andAgQ1(G497A)were constructedwith
a QuikChange Lightning multisite-directed mutagenesis kit (Stratagene)
according to themanufacturer’s protocol. The constructs were all verified
by sequencing. The HHV-6A gQ1 deletion mutant AgQ1("494-497) was
constructed as follows: two gQ1 fragments were amplified using two
primer pairs (underlines indicate the NotI or XhoI site, as specified), 5=-
TCGGACAAGCTGGGCACGTATTTTAC-3= and 5=-ACCAGCGGCCG
CTCAAGTCCTCACGACAGTAGG-3= (NotI) and 5=-ACCCTCGAGCC
ACCATGGCAACCGCAAGACTG-3= (XhoI) and 5=-AAATACGTGCCC
AGCTTGTCCGAGGTGTTTATATAC-3=. The mixed fragments were
used as the template for the next PCR, which used primers 5=-ACCCTC
GAGCCACCATGGCAACCGCAAGACTG-3= (XhoI) and 5=-ACCAGC
GGCCGCTCAAGTCCTCACGACAGTAGG-3= (NotI). The amplified
PCR product was digested with XhoI and NotI, separated by agarose gel
electrophoresis, purified, and cloned into XhoI/NotI-digested pcDNA
3.1(#). AgQ1(494AAAA497) was constructed similarly with the primer
pair 5=-AGCCGCAGCTGCAGCTTGTCCGAGGTGTTTATATAC-3=
and 5=-GACAAGCTGCAGCTGCGGCTGGGCACGTATTTTACAAT
C-3=. The CD46-expressing vector pM18S was a generous gift from T.
Seya, Hokkaido University, Hokkaido, Japan (30).
Transfections. 293T cells were transfectedwith the indicated plasmids
by using Lipofectamine 2000 reagent (Invitrogen). The transfected cells
were harvested at 48 hposttransfection and lysedwithTNEbuffer (10mM
Tris-HCl [pH 7.8], 1% Nonidet P-40, 0.15 M NaCl, 1 mM EDTA) con-
taining a cocktail of protease inhibitors (Roche). The lysates were cleared
by centrifugation at 200,000 $ g for 1 h at 4°C. The supernatants were
resolved with sample buffer (32 mM Tris-HCl [pH 6.8], 1.5% SDS, 5%
glycerol, 2.5% 2-mercaptoethanol) for SDS-PAGE or used for immuno-
precipitation.
Antibodies. The monoclonal antibodies (Mabs) designated AgQ 1-1
and gH F5 were obtained by immunizing mouse footpads with UV-inac-
tivatedHHV-6A (strainGS) virions (27). Lymphocytes from the popliteal
lymph nodes were subsequently retrieved and fused with the nonproduc-
ing myeloma cell line SP2. The hybridoma cells secreting Mabs for
HHV-6A were selected by immunofluorescence antibody assay (IFA).
Next, the selected Mabs were examined with the neutralizing assay de-
scribed elsewhere (27). The Mabs designated AgQ1-119, AgL4, gH1-1,
and AgQ2B were described previously (24).
Nuclei were counterstained with 4=,6-diamidino-2-phenylindole
(DAPI). Fluorescein isothiocyanate (FITC)-conjugated rabbit anti-
mouse immunoglobulin (Dako) was used as a secondary antibody.
Immunofluorescence assay.The IFAwas performed as described pre-
viously (22). Specific immunofluorescence was observed with a fluores-
cence microscope (Nikon) at$400 magnification.
Virus neutralization assay. The virus neutralization assay was per-
formed as described previously (27). Virus titers were determined bymea-
suring the 50% tissue culture infective dose (TCID50) (31).
Immunoprecipitation and Western blot assays. The immunopre-
cipitation assay andWestern blotting were performed as described previ-
ously (24).
CD46 binding assay. The CD46 binding assay was performed as de-
scribed previously (24). Briefly, an anti-CD46 antibody was incubated
with protein G-Sepharose and then cross-linked with protein G-Sephar-
ose, followed by incubation with CD46-expressing 293T cell lysates. Cell
extracts were immunoprecipitated with the protein G-Sepharose-bound
antibody. The boundproteinswere elutedwith 0.1Mglycine (pH2.5) and
neutralized with 1 M Tris-HCl (pH 9.0).
Construction of gQ1 mutant and its revertant. RecA-mediated re-
combination was performed as described previously (32–35), with some
modifications.We used pST76A-SR for the shuttle vector.We first cloned
two homology arms (“gQ1 up” arm, bp 146765 to 147808, and “gQ1
down” arm, bp 150281 to 151227, of the U1102 genome) into the shuttle
vector. The gQ1 up arm was amplified from the U1102 genome by PCR
with primers 5=-ACAGCGGCCGCGAGCTCAGTAATTCGTTACTATG
AG-3= (underlining indicates the NotI site and italics indicate the SacI
site) and 5=-ACCGGTACCTGACCGTTATGTGCGCGTG-3= (underlin-
ing indicates the KpnI site). The gQ1 down arm was amplified with 5=-A
CCGGTACCATCAGCGCACAAGATCTC-3= (underlining indicates the
KpnI site) and 5=-ACAGGATCCGTCGACTCCGTCTCCCGGAGAAA
C-3= (italics indicate the BamHI site and underlining the SalI site). The
PCR product was digested with NotI and KpnI (gQ1 up arm) and with
KpnI and SalI (gQ1 down arm). The fragments were then ligated with
pBluescript SK(#), which had been digested with NotI and SalI, followed
by sequencing to confirm the lack of PCR-generated mutations. The re-
sultant plasmid was digested with SacI and BamHI and ligated with the
shuttle vector pST76A-SR,which had been digestedwith SacI andBamHI.
We named the construct pST76A-SR-full"gQ1. Next we cloned the gQ1
up arm, wild-type gQ1, and gQ1 down arm (bp 146765 to 151227 of the
U1102 genome) into the shuttle vector, to create pST76A-SR-gQ1 wild
type.
We generated gQ1 mutant bacterial artificial chromosome (BAC)
DNA, HHV-6ABACgQ1("494-497), in two steps. In the first step,
pST76A-SR-full"gQ1 was electroporated into DH10B electrocompetent
cells harboring wild-type HHV-6A BAC and plated on LB plates contain-
ing 17!g/ml chloramphenicol (Cm) and 50!g/ml ampicillin (Amp). Ten
to 30 colonies were picked, dilutedwith LBmedium, plated onto LB plates
containing Cm and Amp, and incubated at 43°C overnight. Six to 10
colonies were picked, diluted 10,000 times with LB medium containing
5% sucrose, and plated onto LB plates containing Cm and 5% sucrose.
Colonies growing on these plates were selected by plating single clones
onto Cm-containing and Cm- and Amp-containing plates. Cm-resistant
but Amp-sensitive clones were tested by PCR. The selected clones were
confirmed by digesting the BAC DNA with BamHI. We named the resul-
tant BAC HHV-6ABACfull"gQ1. In the second step, using DH10B elec-
trocompetent cells harboring HHV-6ABACfull"gQ1 and pST76A-
SR-gQ1("494-497), we constructed HHV-6ABACgQ1("494-497) as
described for the first step. The mutation of gQ1 was confirmed by se-
quencing the isolated BAC DNA. HHV-6ABACgQ1("494-497)rev was
constructed in the same way.
Reconstitution of infectious virus using HHV-6A BACs. The de-
tailed method for reconstituting infectious virus using HHV-6A BACs
was described previously (24, 25).
RESULTS
Generation of AgQ1 carboxyl truncation mutants and their re-
activity with an HHV-6A-neutralizing Mab. To analyze HHV-
6A’s entry mechanism in detail, we first sought to produce neu-
tralizing antibodies for HHV-6A, and we obtained several
monoclonal antibodies (Mabs) that could block virus infection.
One of them was against HHV-6A gQ1 (AgQ1), which we named
AgQ 1-1. Therefore, to elucidate the role of gQ1 in HHV-6A in-
fection, we analyzed this neutralizingMab and its recognition site
on gQ1 in detail.
TheMab AgQ 1-1 neutralized HHV-6A but not HHV-6B, and
it specifically recognized AgQ1 (data not shown). In a virus neu-
tralization assay, a 4,000-fold dilution of purified Mab AgQ 1-1
(0.89 mg/ml) completely blocked HHV-6A strain GS infection at
4.0$ 104 TCID50/ml, while a control antibody (AgHgL-A2) never
blocked the infection.
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Recently, we also produced a neutralizing Mab against
HHV-6B gQ1 (BgQ1) and determined the critical domain on
BgQ1 for thatMab’s recognition (27).Here, we similarly sought to
identify the recognition site(s) for Mab AgQ 1-1. For this, we first
constructed AgQ1 carboxyl-terminal truncation mutants and ex-
amined their reactivitywithMabAgQ1-1 by IFA.As shown in Fig.
1, the mutant with a C-terminal truncation beginning at residue
504 was recognized by the Mab, while the one with its truncation
beginning at residue 492 was not. These results suggested that the
important site(s) forMabAgQ1-1 recognitionwas between residues
492 and 504. Surprisingly, the critical site for recognition was com-
pletely the sameas that forKH-1, theneutralizingMab forBgQ1(27).
In contrast, another Mab, AgQ1-119, which has an N-terminal (be-
tweenaminoacids3and422) linear epitopeonAgQ1, reactedwithall
the truncationmutants depicted in Figure 1.
TheAgQ1 amino acid residues around 496 are important for
its recognition by Mab AgQ 1-1. The results shown in Figure 1
suggested that the sequence between amino acid residues 492 and
504 of HHV-6A strain U1102 gQ1 might contain an epitope for
Mab AgQ 1-1. We next searched for U1102-specific amino acid
residue(s) in this region by comparing the gQ1 amino acid se-
quence of HHV-6A U1102 and HHV-6B strain HST, because the
Mab recognized HHV-6A but not HHV-6B. As shown in Figure
2A, only Gln 496 in this region was U1102 specific; this residue in
HST was Glu. We therefore constructed a mutant AgQ1 in which
Gln496was replacedwithGlu, AgQ1(Q496E) (Fig. 2B) and exam-
ined its reactivity with Mab AgQ 1-1. Unexpectedly, this mutant
did react withMab AgQ 1-1 with reactivity similar to that of wild-
type AgQ1 (Fig. 3B), which suggested that this region was not the
epitope of the Mab AgQ 1-1.
To analyze this region in more detail, we constructed substitu-
tion mutants and a deletion mutant, depicted in Figure 2B. A
deletion mutant lacking residues 494 to 497, AgQ1("494-497),
and a mutant with serial substitutions, AgQ1(494AAAA497), did
not react with Mab AgQ 1-1 at all (Fig. 3B). The expression of
all the mutants was confirmed by Western blotting (Fig. 3A)
and IFA (Fig. 3B) with Mab AgQ1-119. On the other hand, the
single-substitution mutants AgQ1(L494A), AgQ1(C495A),
AgQ1(Q496A), andAgQ1(G497A) showed reactivitywithMabAgQ
1-1, although the reactivity of AgQ1(C495A) was severely impaired
(Fig. 3B). Since Mab AgQ 1-1 does not react in Western blots (data
not shown), we used the AgQ1-119Mab forWestern blotting.
Mab AgQ 1-1 seemed to have a conformational epitope, be-
FIG 1 Schematic diagram of HHV-6A gQ1 mutants with various carboxyl-terminal deletions and their reactivity with Mab AgQ 1-1. 293T cells were cotrans-
fected with wild-type AgQ1 or one of its deletion mutants and AgQ2. The transfected cells were harvested 48 h after transfection and subjected to staining with
anti-gQ1 Mabs AgQ 1-1 and AgQ1-119. The reactivities to the Mabs are shown at right.
FIG2 Amino acid sequence comparison betweenHHV-6A gQ1 andHHV-6B
gQ1 and schematic representation of HHV-6A gQ1 mutants. (A) Amino acid
sequence comparison of gQ1, from amino acid 492 to 504, between strains
U1102 and HST. The differences between these sequences are indicated by
underlines. (B) Wild-type AgQ1 and its mutants constructed in this study.
Underlines indicate the mutated amino acids.
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FIG3 AgQ1 region recognized by the neutralizingMabAgQ1-1. 293T cells were transfectedwithwild-type ormutant AgQ1withAgQ2, AgH, andAgL. The cells
were harvested at 48 h posttransfection. (A) The cells were lysed and immunoblotted with the Mab AgQ1-119. WB, Western blotting. (B) The transfected cells
were fixed and stained with Hoechst 33258 or with the Mab against AgQ1 (AgQ 1-1 or AgQ1-119) or AgQ2 (AgQ2B).
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cause the reactivity to AgQ1 clearly increased in the presence of
AgQ2, AgH, and AgL (Fig. 3B). In addition, we previously showed
that AgQ1 maturation occurs only when all four components,
AgH, AgL, AgQ1, and AgQ2, are coexpressed (24). Therefore, the
reactivity for Mab AgQ 1-1 was analyzed in the presence of AgH,
AgL, and AgQ2. Wild-type or mutant gQ1 showed greater reac-
tivity to Mab AgQ 1-1 in the presence of AgH, AgL, and AgQ2
compared to the reactivity when gQ1 was expressed alone or
coexpressed with only gQ2, although AgQ1("494-497) and
AgQ1(494AAAA497) showed no reactivity(data not shown).
These results indicated that the amino acid residues around posi-
tions 494 to 497 were a critical site for Mab AgQ 1-1 recognition,
although they were thought not to be the epitope of the Mab.
The amino acid residues around position 496 are important
for AgQ1 maturation and AgH/AgL/AgQ1/AgQ2 complex for-
mation.Next, we performed immunoprecipitation with the Mab
FIG 4 Detection of wild-type AgQ1 or its various mutants using the Mab AgQ 1-1. 293T cells were cotransfected with wild-type or mutant HHV-6A gQ1 with
AgH,AgL, andAgQ2. Forty-eight hours later, the cells were harvested, lysed, and immunoprecipitated (IP)with the anti-gQ1Mab, AgQ1-1, followed byWestern
blotting (WB) with Mabs for AgQ1 (AgQ1-119), gH (gH1-1), gL (AgL4), and gQ2 (AgQ2B).
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AgQ 1-1. As predicted, when AgQ1("494-497) and AgQ1(494AA
AA497) were coexpressed with AgH, AgL, and AgQ2, Mab AgQ
1-1 could not immunoprecipitate any component (Fig. 4). In con-
trast, when wild-type gQ1, AgQ1(L494A), AgQ1(Q496A),
AgQ1(Q496E), or AgQ1(G497A) was coexpressed with the other
three molecules, Mab AgQ 1-1 could coimmunoprecipitate all of
the components. In the case of AgQ1(C495A), although gQ1 and
gH could be detected faintly, gL and gQ2 could be scarcely de-
tected.
We previously showed that with AgQ1’s maturation, its size
shifted from 74 kDa (gQ1-74K), the immature form, to 80 kDa,
themature form (gQ1-80K); this shift also occurred only when all
four components were coexpressed (24). Based on the report, the
Western blot assay done here showed that the mature gQ1-
80K form of AgQ1(Q494A), AgQ1(C495A), AgQ1(Q496A),
AgQ1(Q496E), AgQ1(G497A), or wild-type AgQ1 could be de-
tected, while that of AgQ1(C495A) could be detected but only
faintly (Fig. 4, left panels). On the other hand, the gQ1-80K form
of AgQ1 ("494-497) and AgQ1(494AAAA497) could not be de-
tected at all, even when cotransfected with AgH, AgL, and AgQ2,
similar to the results seen in AgH, AgL, and AgQ1 (wild type)
transfections, used as a negative control for maturation (Fig. 4).
These results may show that this region is also critical for gH/gL/
gQ1/gQ2 complex formation, since we have previously shown
that gH/gL/gQ1/gQ2 complex formation occurs only when gH,
gL, gQ1, and gQ2 are coexpressed (24).
Therefore, to confirm this, we did coimmunoprecipitation ex-
periments by using anti-gH Mab. As expected, AgQ1("494-497)
and AgQ1(494AAAA497) could not be immunoprecipitated with
anti-gHMab (Fig. 5). In contrast, AgQ1(Q494A), AgQ1(C495A),
AgQ1(Q496A), AgQ1(Q496E), AgQ1(G497A), or wild-type
AgQ1 could be immunoprecipitated, although AgQ1(C495A)
could barely be detected. These findings collectively show that the
amino acid residues around position 496 of AgQ1 are important
FIG 5 Confirmation of complex formation of HHV-6A gH/gL/gQ2 with wild-type ormutant AgQ1.Wild-type HHV-6A gQ1 or eachmutant was cotransfected
with AgH, AgL, and AgQ2. Forty-eight hours later, the cells were harvested, lysed, and immunoprecipitated (IP) with an anti-gH Mab, gH F5, followed by
Western blotting (WB) with Mabs for AgQ1 (AgQ1-119), gH (gH1-1), gL (AgL4), and gQ2 (AgQ2B).
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FIG 6 Interaction of AgH/AgL/AgQ1 (wild type or each mutant)/AgQ2 with CD46. 293T cells were cotransfected with AgH, AgL, AgQ2, and wild-type or
mutant AgQ1, and 48 h later, the cell lysates were prepared and used for a CD46 binding assay. CD46 protein was isolated from 293T cells transfected with a
CD46-expressing plasmid using an anti-CD46Mab cross-linked to protein G-Sepharose. The Sepharose was then incubated with the cell extracts, shown in the
left panels, and the eluates from the Sepharose were blotted with the indicated Mabs, shown in the right panels.
Maeki et al.
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for both gQ1 maturation and gH/gL/gQ1/gQ2 complex forma-
tion, and the region from position 494 to 497 is essential for them.
The amino acid residues around 496 are also essential for
binding toCD46.HumanCD46 is a cellular receptor forHHV-6A
(21), and the HHV-6A gH/gL/gQ1/gQ2 complex is its ligand (22,
23). We previously showed that the binding of AgQ1 to CD46 can
be detected only when all three of the other components are co-
expressed with AgQ1 (24). Therefore, we examined whether
each gQ1 mutant could bind to CD46 when coexpressed with
the other three components of the complex. As predicted, the
binding of AgQ1("494-497) and AgQ1(494AAAA497) to CD46
could not be detected, although AgQ1(Q496A), AgQ1(Q496E),
AgQ1(G497A), or wild-type AgQ1 could bind to CD46 (Fig. 6).
Surprisingly, the CD46 binding of AgQ1(L494A) was very weak,
although it could form the gH/gL/gQ1/gQ2 complex. As pre-
dicted, an interaction of AgQ1(C495A) with CD46 was not seen.
This result shows that the amino acid residues around position
496 are also important for binding to CD46 and the region from
position 494 to 497 is essential for it.
MabAgQ1-1doesnot immunoprecipitateCD46 fromHHV-
6A-infected cells.We next analyzed the relationship between the
Mab AgQ 1-1 determinant and the CD46 binding domain in
HHV-6A-infected cells. For this, we examined whether Mab AgQ
1-1 could coprecipitate CD46 in HHV-6A strain GS-infected
HSB-2 cell lysates. CD46 was not coprecipitated byMab AgQ 1-1,
while CD46 was coprecipitated withMab AgQ1-119 (Fig. 7), sug-
gesting thatMabAgQ1-1 blocksHHV-6A infection by interfering
with CD46 binding.
We finally analyzed whether the amino acid residues around
position 494 to 497 of AgQ1 are also essential for viral replication,
because this region is essential for gH/gL/gQ1/gQ2 complex for-
mation and binding to CD46. In fact, infectious virus could not be
reconstituted from the HHV-6ABACgQ1("494-497) genome,
while its revertant virus, rHHV-6ABACgQ1("494-497)rev, could
be rescued (data not shown).
DISCUSSION
We previously reported that the HHV-6A gH/gL/gQ1/gQ2 com-
plex binds to CD46 (24). In the present study, we established a
neutralizing Mab, AgQ 1-1, which specifically reacted with
HHV-6A gQ1 but not with HHV-6B gQ1, and analyzed its char-
acteristics.
The Mab AgQ 1-1 was thought to have a conformational
epitope, because its reactivity to AgQ1 clearly increased in the
presence of AgQ2, AgH, andAgL (Fig. 3) and it did not react in the
Western blot assay.
To determine the recognition site(s) of the Mab AgQ 1-1, we
constructed several C-terminal deletionmutants of HHV-6A gQ1
and examined whether they could react with Mab AgQ 1-1. The
important domain for the Mab recognition appeared to lie be-
tween the amino acid residues at positions 496 and 504 (Fig. 1).
Interestingly, in HHV-6B gQ1, this region is important for react-
ing with HHV-6B’s neutralizing Mab, KH-1 (27). Although the
only amino acid in this region that is different in HHV-6A and -B
is Glu 496 of HHV-6B, the replacement of this amino acid with
Gln did not affect KH-1’s recognition (27). In addition, the re-
placement of this region in HHV-6A gQ1 with the homologous
domain from HHV-6B gQ1 did not abrogate its recognition by
Mab AgQ 1-1. This shows that although the epitope for the Mab
AgQ 1-1 did not exist within this region, the region appears to be
important for AgQ1’s recognition by Mab AgQ 1-1, because
AgQ1("494-497) and AgQ1(494AAAA497) showed no reactivity
with the Mab at all, even in the presence of gH, gL, and gQ2 (Fig.
3). Therefore, we further analyzed the region in detail by con-
structing other mutants, as depicted in Figure 2.
From the results with AgQ1("494-497) and AgQ1(494AAAA
497), we found that this region was also essential for HHV-6A
gH/gL/gQ1/gQ2 complex formation (Fig. 5) and for its binding to
CD46 (Fig. 6). To investigate whether this region is also essential
for virus replication, we constructed an HHV-6A BAC genome
with themutated gQ1, AgQ1("494-497), and tried to reconstitute
the infectious virus from the genome. As predicted, infectious
virus could not be reconstituted, but its revertant virus could be
(data not shown), indicating that this region is also essential for
virus infection.
Since this region was thought to be important for AgQ1’s
proper folding, we next replaced amino acids around position 496
and analyzed the characteristics of the mutants. The characteris-
tics of the wild type and each mutant are summarized in Table 1.
The mutants AgQ1(Q496A) and AgQ1(G497A) showed levels of
TABLE 1 Summary of characteristics of wild type and mutants of AgQ1
Protein Reactivitya
Complex
formation CD46 binding
AgQ1 wild type % % %
AgQ1(L494A) % % &b
AgQ1(C495A) &b &b #
AgQ1(Q496A) % % %
AgQ1(Q496E) % % %
AgQ1(G497A) % % %
AgQ1("494-497) # # #
AgQ1(494AAAA497) # # #
a Reactivity to the Mab AgQ 1-1 in IFA (Fig. 3).
b&, reactivity to the Mab AgQ 1-1 or interaction between each component seemed to
be severely impaired, or binding to CD46 could hardly be detected.
FIG 7 Mab AgQ 1-1 does not immunoprecipitate CD46 from HHV-6A-in-
fected cells. Lysates fromHHV-6A strain GS-infectedHSB-2 cells were immu-
noprecipitated with the antibodies indicated above the gels. The immunopre-
cipitates were blotted with anti-gQ1 (top) and anti-CD46 (bottom) Mabs.
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reactivity toMab AgQ 1-1 in the presence of AgH, AgL, and AgQ2
that were similar to the reactivity of wild-type AgQ1 (Fig. 3). In
addition, they could form the gH/gL/gQ1/gQ2 complex and bind
toCD46 aswell as wild-typeAgQ1 orAgQ1(Q496E) (Fig. 4, 5, and
6). However, AgQ1(C495A) showed much less reactivity to Mab
AgQ 1-1 even in the presence of AgH, AgL and AgQ2 (Fig. 3).
Furthermore, the interaction of AgQ1(C495A) with gH, gL, and
gQ2 seemed to be severely impaired (Fig. 4). In addition, the com-
plex containing AgQ1(C495A) could not bind to CD46 (Fig. 6),
indicating that gQ1(C495A) with gH, gL, and gQ2 might not be
folded properly. Surprisingly, the interaction of the complex con-
taining AgQ1(L494A) with CD46was very weak (Fig. 6), although
AgQ1(L494A) showed reactivity to Mab AgQ 1-1 in the pres-
ence of AgH, AgL, and AgQ2 (Fig. 3). Furthermore, unlike
AgQ1(C495A), that substitution (AgQ1 494 L¡ A) did not seem
to affect the interaction of AgQ1(L494A) with gH, gL, and gQ2
(Fig. 4). The discrepancy may be explained by two possibilities.
First, the CD46 binding domain of AgQ1 might exist within this
region. Second, this region might be critical for maintaining the
conformation of the CD46 binding domain, although it is not the
direct binding site. Consistent with this, the results shown in Fig-
ure 7 suggested that the Mab AgQ 1-1 might interfere with the
binding of CD46 to its ligand, the gH/gL/gQ1/gQ2 complex.
Therefore, since the amino acids around position 496 might not
be the epitope of the Mab AgQ 1-1, if this region overlaps the
CD46 binding domain, the epitope of the Mab AgQ 1-1 should
exist in some other region. If this region does not overlap the
CD46 binding domain, the epitope of the Mab AgQ 1-1 may or
may not exist in the CD46 binding domain. AgQ2 bands were
barely visible in the data obtained here. Since it seemed to be
difficult to detect it by Western blotting, this might be explained
by low expression of gQ2 or its specific structure.
We previously produced a neutralizing Mab to BgQ1, named
KH-1, by immunizingmice withUV-inactivatedHHV-6B virions
(27). Interestingly, we determined that the critical domain for the
recognition of Mab AgQ 1-1, which we produced by immunizing
mice with UV-inactivated HHV-6A virions, is completely the
same as that of Mab KH-1. Furthermore, KH-1 showed reactivity
similar to the reactivities of mutants with single amino acid sub-
stitutions, like Mab AgQ 1-1. In other words, KH-1 did react to
BgQ1(E488Q) to an extent similar to the reactivity of wild-type
BgQ1 (BgQ1 488E corresponds to AgQ1 496Q), and the levels of
reactivity to mutants with its neighboring amino acid substitu-
tions were significantly decreased (27). However, some point mu-
tantswithmutations aroundBgQ1 488Edid not show reactivity to
KH-1, although all the point mutants with mutations around
AgQ1 496Q showed reactivity. We think this difference mainly
comes from the difference of the presence of AgH and AgL; we
performed IFA with Mab AgQ 1-1 in the presence of AgH, AgL,
andAgQ2.On the other hand, the reactivity to BgQ1was analyzed
only in the presence of BgQ2. We found that the reactivity of
AgQ1pointmutants toMabAgQ1-1 clearly increasedmore in the
presence of AgQ2, AgH, and AgL than only in the presence of
AgQ2 (data not shown). Since both Mabs AgQ 1-1 and KH-1 are
neutralizingMabs, the amino acid residues aroundposition 496 of
AgQ1, which corresponds to 488 of BgQ1, are conserved and
thought to be critical for virus entry, although they are thought
not to be the epitope of the neutralizing Mabs.
Here, we identified a domain of AgQ1 that is critical for main-
taining its functional conformation. Although the structure of its
receptor, CD46, has been determined (36, 37), the crystal struc-
tures of gQ1/gQ2 or gH/gL/gQ1/gQ2 have not been reported. In
other herpesviruses, structure-based mutagenesis had been re-
ported to identify functional domains of gH and gB (38–40). The
conformation of the HHV-6A gH/gL/gQ1/gQ2 complex needs to
be determined to elucidate the functional and conformational
changes of the envelope and host membrane, which will help re-
veal the entry mechanism of HHV-6A.
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